Trials / Completed
CompletedNCT02482077
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients
Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 2 Infection
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 112 (actual)
- Sponsor
- Humanity and Health Research Centre · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of Sofosbuvir containing regimens in treatment-naive or treatment-experienced patients with HCV genotypes 2 infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SOF+RBV | Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg). |
| DRUG | SOF+DCV | Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60mg tablet administered once daily. |
| DRUG | LDV/SOF | Ledipasvir 90 mg /Sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2017-12-31
- Completion
- 2018-03-15
- First posted
- 2015-06-25
- Last updated
- 2018-03-19
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02482077. Inclusion in this directory is not an endorsement.